147 related articles for article (PubMed ID: 26503199)
1. Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods.
An MW; Han Y; Meyers JP; Bogaerts J; Sargent DJ; Mandrekar SJ
J Clin Oncol; 2015 Dec; 33(34):4048-57. PubMed ID: 26503199
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.
An MW; Dong X; Meyers J; Han Y; Grothey A; Bogaerts J; Sargent DJ; Mandrekar SJ;
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26296640
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.
Mandrekar SJ; An MW; Meyers J; Grothey A; Bogaerts J; Sargent DJ
J Clin Oncol; 2014 Mar; 32(8):841-50. PubMed ID: 24516033
[TBL] [Abstract][Full Text] [Related]
4. On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.
Bruno R; Claret L
Clin Pharmacol Ther; 2009 Aug; 86(2):136-8. PubMed ID: 19621009
[TBL] [Abstract][Full Text] [Related]
5. Analysis of tumor burden versus progression-free survival for Phase II decision making.
Fridlyand J; Kaiser LD; Fyfe G
Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
[TBL] [Abstract][Full Text] [Related]
6. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
7. Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.
Siah KW; Khozin S; Wong CH; Lo AW
JCO Clin Cancer Inform; 2019 Sep; 3():1-11. PubMed ID: 31539267
[TBL] [Abstract][Full Text] [Related]
8. Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.
Knollmann FD; Kumthekar R; Fetzer D; Socinski MA
Clin Lung Cancer; 2014 Mar; 15(2):103-9. PubMed ID: 24361250
[TBL] [Abstract][Full Text] [Related]
9. The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database.
Litière S; de Vries EGE; Seymour L; Sargent D; Shankar L; Bogaerts J;
Eur J Cancer; 2014 Jul; 50(10):1847-1853. PubMed ID: 24726734
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study.
Toffart AC; Moro-Sibilot D; Couraud S; Merle P; Perol M; Girard N; Souquet PJ; Mastroianni B; Ferretti GR; Romand P; Chatellain P; Vesin A; Brambilla E; Brambilla C; Timsit JF
BMC Cancer; 2014 Dec; 14():989. PubMed ID: 25527907
[TBL] [Abstract][Full Text] [Related]
11. Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
Bruno R; Marchand M; Yoshida K; Chan P; Li H; Zou W; Mercier F; Chanu P; Wu B; Lee A; Li C; Jin JY; Maitland ML; Reck M; Socinski MA
Clin Cancer Res; 2023 Mar; 29(6):1047-1055. PubMed ID: 36595566
[TBL] [Abstract][Full Text] [Related]
12. Verification of the correlation between progression-free survival and overall survival considering magnitudes of survival post- progression in the treatment of four types of cancer.
Liu LY; Yu H; Bai JL; Zeng P; Miao DD; Chen F
Asian Pac J Cancer Prev; 2015; 16(3):1001-6. PubMed ID: 25735320
[TBL] [Abstract][Full Text] [Related]
13. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
[TBL] [Abstract][Full Text] [Related]
14. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
16. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
17. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials.
An MW; Mandrekar SJ; Branda ME; Hillman SL; Adjei AA; Pitot HC; Goldberg RM; Sargent DJ
Clin Cancer Res; 2011 Oct; 17(20):6592-9. PubMed ID: 21880789
[TBL] [Abstract][Full Text] [Related]
18. Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial.
Król A; Ferrer L; Pignon JP; Proust-Lima C; Ducreux M; Bouché O; Michiels S; Rondeau V
Biometrics; 2016 Sep; 72(3):907-16. PubMed ID: 26890381
[TBL] [Abstract][Full Text] [Related]
19. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer.
de Marinis F; Pereira JR; Fossella F; Perry MC; Reck M; Salzberg M; Jassem J; Peterson P; Liepa AM; Moore P; Gralla RJ
J Thorac Oncol; 2008 Jan; 3(1):30-6. PubMed ID: 18166838
[TBL] [Abstract][Full Text] [Related]
20. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
